FDA says Medolife sold unapproved Escozine drugs online with claims to treat cancer, HIV, and COVID-19.
What happened
In April 2023, FDA reviewed www.medolife.com and www.medoliferx.com and found Escozine-HP and several Escozine Immunapen products offered for sale in the United States. The websites claimed these products treat cancer, HIV, and COVID-19, among other serious conditions. FDA determined the products are unapproved new drugs and that no FDA-approved drug application is in effect for them.
What FDA found
FDA says the Escozine products are drugs because the websites claim they treat cancer, HIV, COVID-19, and other diseases, or affect body structure or function.
FD&C Act §201(g)(1), 21 U.S.C. 321(g)(1)FDA says the products are 'new drugs' because they are not generally recognized as safe and effective for those uses.
FD&C Act §201(p), 21 U.S.C. 321(p)FDA says no approved new drug application is in effect for the products.
FD&C Act §505(a), 21 U.S.C. 355(a)FDA says selling or shipping the products across state lines violates the law because they are unapproved new drugs.
FD&C Act §§301(d) and 505(a), 21 U.S.C. 331(d) and 355(a)FDA says labeling the products as homeopathic does not exempt them from drug approval, adulteration, or misbranding requirements.
FD&C Act §201(g)(1), 21 U.S.C. 321(g)(1)FDA says a pre-IND filing—an early step before human testing—is not an approved drug application or an IND, which is FDA permission to test a drug in humans.
21 CFR Part 312
What FDA wants
FDA asks the company to notify it in writing within 15 working days of receipt, with the specific steps taken to correct the violations, how it will prevent recurrence, and supporting documents. If correction cannot be completed in that time, the company must state why and when it will finish.
Who should pay attention
- companies making homeopathic or supplement products with disease claims
- retailers and brands that sell Escozine products
- drug sponsors that cite pre-IND status in marketing
This is a summary. Read the original letter on fda.gov.